AVERT Shock: Arginine Vasopressin During the Early Resuscitation of Traumatic Shock
Status:
Completed
Trial end date:
2016-09-06
Target enrollment:
Participant gender:
Summary
Trauma patients, who are transfused with multiple blood products to treat shock due to blood
loss, frequently develop inappropriately low vasopressin levels. Vasopressin is a hormone
necessary to maintain an adequate blood pressure and low levels have been associated with the
need for increased transfusions, vasopressors and additional morbidity. Vasopressin is
routinely used in the ICU to treat septic shock and other disease processes resulting in
decreased vasopressin levels and low blood pressure. This study will investigate the
potential benefit of early vasopressin supplementation during the resuscitation of trauma
patients and the applicability of using copeptin as a vasopressin biomarker. Trauma patients
who receive 6 or more units of blood product within 12 hours of arrival will be randomized to
receive a vasopressin bolus plus infusion or a similar volume of a placebo (normal saline)
for 48 hours. Serial blood samples will be taken for 5 days post-injury. Clinical and
demographic data will be recorded prospectively.
Phase:
Phase 2
Details
Lead Sponsor:
University of Pennsylvania
Collaborators:
National Trauma Research Institute United States Department of Defense